Cheleka

In a recent paper by Markewitz, et al., the researchers aimed to investigate and determine the levels of anti-SARS-CoV-2 antibodies in individuals who have been vaccinated with a mRNA COVID-19…

In a recent study, Wu, et al., aimed to develop a messenger ribonucleic acid (mRNA) vaccine using the SARS-CoV-2 Omicron variant sequence as a target. The aim was to develop…

In a recent study, researchers have demonstrated that the SARS-CoV-2 receptor-binding domain (RBD)-based, sortase A-conjugated nanoparticle (RBD-scNP) vaccine induces neutralizing antibodies (NAbs) in non-human primates (NHPs) against all eight variants of SARS-CoV-2.

8 September 2021 In a recent Pre-print, Keeton et al., examined the effect of prior infection with ancestral (D614G) or Beta variants on Ad26.COV2.S immunogenicity approximately 28 days...

In a recent preprint, Riou and colleagues aimed to provide an overall measure of immune evasion by assessing neutralizing antibody and T cell responses in 44 South African COVID-19 patients…

Researcher aimed to develop a candidate SARS-Cov-2 vaccine that uses the YF17D vaccine as a vector to express a non-cleavable pre-fusion form of the SARS-CoV-2 spike antigen (YF-S0).

There are currently multiple trials that are investigating different strategies such as SARS-CoV-2 vector vaccine prime followed by an mRNA vaccine boost and vice versa. In this summary, we report…